Kyriakidis Ioannis, Tragiannidis Athanasios, Zündorf Ilse, Groll Andreas H
2nd Department of Pediatrics, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece.
Institute of Pharmaceutical Biology, Goethe-University of Frankfurt, Frankfurt am Main, Germany.
Mycoses. 2017 Aug;60(8):493-507. doi: 10.1111/myc.12621. Epub 2017 Apr 26.
An expanding list of immunomodulatory or immunosuppressive monoclonal antibodies (mAbs) and biologic therapeutics is currently entering clinical practice, particularly in the areas of oncology, transplantation and autoimmune disorders. These agents are directed against molecules or cells involved in inflammation and immunity and may therefore be associated with serious and opportunistic infections. The purpose of this review was to critically analyse the literature on invasive fungal infections (IFIs) occurring in association with mAbs and fusion proteins other than tumour necrosis alpha (TNF-α) inhibitors, including therapeutics modulating T-cell-mediated pathologies (muromonab, abatacept, belatacept, ipilimumab, basiliximab, daclizumab), inducing lymphopenia (alemtuzumab), depleting CD20+ B cells (rituximab) and interfering with various targets (anakinra, natalizumab, blodalumab, ixekizumab and others) with a focus on children, and to provide a framework of evaluating the risk for IFIs in this population.
目前，越来越多的免疫调节或免疫抑制单克隆抗体（mAb）和生物疗法正在进入临床实践，尤其是在肿瘤学、移植和自身免疫性疾病领域。这些药物针对参与炎症和免疫的分子或细胞，因此可能与严重感染和机会性感染有关。本综述的目的是批判性地分析与mAb和除肿瘤坏死因子α（TNF-α）抑制剂之外的融合蛋白相关的侵袭性真菌感染（IFI）的文献，包括调节T细胞介导病理的疗法（莫罗单抗、阿巴西普、贝拉西普、伊匹木单抗、巴利昔单抗、达利珠单抗）、诱导淋巴细胞减少的疗法（阿仑单抗）、消耗CD20+B细胞的疗法（利妥昔单抗）以及干扰各种靶点的疗法（阿那白滞素、那他珠单抗、布洛达单抗、司库奇尤单抗等），重点关注儿童，并提供评估该人群IFI风险的框架。
